Topic:

Venture Capital

Latest Headlines

Latest Headlines

China's Innovent banks $100M to cash in on the biosimilar boom

Innovent Biologics has raised $100 million in venture cash in hopes of becoming the premier maker of biotech drugs in its native China, advancing a pipeline of biosimilars and proprietary treatments.

Gene therapy pioneer ReGenX fuels R&D, hiring spree with $30M VC round

Cashing in on the current enthusiasm in venture circles for gene therapy upstarts, ReGenX has snagged a $30 million round that will finance a round of new hires as it sets sail for the clinic with lead programs for rare diseases of the central nervous system.

Novartis teams with Qualcomm on $100M digital health fund

The deal gives Novartis access to the most active digital health VC team--Rock Health reports Qualcomm Ventures has struck 21 deals since 2011--and further strengthens the ties between the two companies.

10X Genomics exits stealth mode with $80M, plan to improve Illumina tech

10X Genomics has exited stealth mode with $80 million in VC funding and a plan to solve a significant sequencing problem without going head to head with Illumina. The Pleasanton, CA-based startup is set to unveil an add-on for Illumina sequencers that improves their ability to map long reads of DNA.

Personalis raises $33M to scale up pharma-facing genomics operation

Personalis has returned to the financing font ahead of a planned scaling up of its operations. The Menlo Park, CA-based genome sequencing and interpretation company has reported interest from pharma companies in its cancer services, a trend that helped persuade investors to give it $33 million in a Series C round.

Big rounds push 2014 biotech venture funding to near-record $6B

With a big assist from Moderna's recent monster round, the biotech industry came within a rounding error of breaking the record for new venture investing in 2014, racking up $5.96 billion in total investments in a frenzied year of deals, data and buyouts, according to The MoneyTree Report by PricewaterhouseCoopers and the National Venture Capital Association based on data from Thomson Reuters.

Canadian VC CTI unveils a $112M new biotech fund

CTI Life Sciences, a Montreal-headquartered biotech backer, has put together a $112 million new purse, scouting for promising startups in Canada and abroad.

NeuroPhage wraps a $27M round to advance its Alzheimer's drug

Cambridge, MA's NeuroPhage banked an additional $10 million in Series D cash, bringing its latest round to $27 million and filling out the biotech's war chest as it marches toward the clinic with a treatment for neurodegenerative disease.

Top biotech investor NEA outlines plans for another $2.5B-plus venture fund

In a sign of the times, leading life sciences venture maven David Mott and his colleagues at New Enterprise Associates have begun raising a whopping $2.5 billion venture fund--less than three years after rolling out its latest fund with $2.6 billion.

Euro VC Fountain unveils a $101M biotech fund

Fountain Healthcare Partners put together an €85 million ($101 million) new purse, money the Irish investor plans to pour into biotech startups.